AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05221879 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Dose adjustment of Enoxaparin in patients with sub-therapuetic (prophylactic) levels of factor 10a
Description: We screened ICU patients who recieved DVT prophylaxis with fixed dose of Enoxaparin (40 mg SC daily) for peak blood levels of factor 10A. For patients who did not achieve therapuetic 10a levels (0.2-0.4) we increased the Enoxaparin dose to 60 mg SC daily.
Study NCT04033900 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Forced air warming devices
Description: In the treatment group, heating will be started with a pre-surgical forced-air blanket Outpatient Warming Blanket model 11101 Bair Hugger from 3M and a forced-air heating unit Bair Hugger Warming Unit Model 775 from 3M at 38-43º C which will be maintain during the stay in the pre-surgery room until the transfer to the operating room
Study NCT01985126 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen
Description: 650 to 1000 mg administered in prophylactic doses by mouth prior to study drug administration.
Study NCT01985126 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diphenhydramine
Description: 25 to 50 mg administered in prophylactic doses by mouth (or equivalent in accordance with local standards) prior to and after study drug administration.
Study NCT01985126 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daratumumab (Part 2)
Description: Based on the Part 1 response rate, Group A or B treatment will be selected as the treatment regimen for participants enrolled in Part 2.
Study NCT00366626 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naltrexone
Description: Naltrexone (25 mg/day for days 1-2 and 50 mg/day for days 3-7)
Study NCT00366626 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo for 7 days matched to Naltrexone
Study NCT01953926 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neratinib
Description: 240 mg administered orally, once daily with food, continuously in 28 day cycles
Study NCT01953926 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: 500 mg administered as two 5 mL injections on Days 1, 15, and 29; then once every 4 weeks thereafter month, then Day 1 of every 4 week cycle
Study NCT01953926 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: Initial dose of 8 mg/kg of trastuzumab administered IV on Day 1, followed by 6 mg/kg IV once every 3 weeks thereafter
Study NCT01953926 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: 80mg/m\^2 administered IV on Days 1, 8, and 15 of every 4 week cycle
Study NCT02255175 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Estradiol
Description: Participants will receive transdermal estradiol (100μg/day) for 3 weeks
Study NCT02255175 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Estradiol
Description: Participants will receive transdermal estradiol (100μg/day) for 3 weeks
Study NCT02255175 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Progesterone
Description: Participants will receive an additional week of combined estradiol and micronized progesterone (200 mg/day) at the end of the study to precipitate menstruation.
Study NCT02255175 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Progesterone
Description: Participants will receive an additional week of combined estradiol and micronized progesterone (200 mg/day) at the end of the study to precipitate menstruation.
Study NCT01602848 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intensive care management and coordination
Description: Care Management Teams comprised of social workers, community based care managers, and dedicated clinicians work to meet patients' needs in both the health care setting and the community. The CIDP model incorporates motivational interviewing, harm reduction, access to housing through our community partners utilizing a Housing First approach, and provides cellular phones for patients when needed, to better enable regular communication with program staff.
Study NCT06163755 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone 40 MG Injection
Description: Intra-articular knee injection will be performed in patient with knee osteoarthritis who meets inclusion criteria. After Random assignment Patient will either get Intra-articular Morphine with Bupivacaine or Depomedrol with Bupivacaine.
Study NCT06163755 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylprednisolone 40 MG Injection
Description: Intra-articular knee injection will be performed in patient with knee osteoarthritis who meets inclusion criteria. After Random assignment Patient will either get Intra-articular Morphine with Bupivacaine or Depomedrol with Bupivacaine.
Study NCT01276587 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D3
Description: Oral vitamin D3 100,000 IU administered monthly for six months in children and adolescents with sickle cell disease
Study NCT03998826 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Piroxicam
Description: 20mg piroxicam
Study NCT03998826 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo
Study NCT00433069 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pioglitazone
Description: Increase early virological response to pegylated interferon alpha plus ribavirin by increasing insulin sensitivity
Study NCT00433069 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interferon Alfa-2a
Description: Standard of care for chronic hepatitis C
Study NCT00433069 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: Standard of care for chronic hepatitis C
Study NCT03603431 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MRG-110
Description: Single ascending doses of MRG-110
Study NCT03603431 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Single doses of placebo
Study NCT03603431 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single doses of placebo
Study NCT03603431 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MRG-110
Description: Multiple ascending doses of MRG-110
Study NCT03603431 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Multiple doses of Placebo
Study NCT03603431 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Multiple doses of Placebo
Study NCT03031405 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin nasal spray
Study NCT03031405 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Placebo nasal spray
Study NCT01027884 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (900 mg/day) 2 tabl (150 mg each) x 3 times orally with meals
Study NCT01027884 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Idebenone
Description: Idebenone (900 mg/day) 2 tabl (150 mg each) x 3 times orally with meals
Study NCT01788059 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: injection the mesenchymal stem cell in non union site
Study NCT00420160 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Smoking cessation treatment plus moderate intensity exercise
Study NCT00420160 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Smoking cessation treatment plus health education
Study NCT01187160 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transoral robotic surgery (TORS)
Description: The da Vinci® Robotic Surgical System (Intuitive Surgical, Inc., Sunnyvale, CA) is a manual image-guided surgery system that is computer enhanced rather than computer guided robotic surgery in which the surgeon programs the computer to do the surgery and the robot does the surgery (also known as a milling device). Use of the da Vinci® Robotic Surgical System in the aforementioned configuration in fact facilitates an exact translation of the surgeons hand and finger movements at the console to precise and tremor-free movements of the arms and instruments.
Study NCT00184431 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical therapy technique and exercises
Description: The experimental group receives task specific physical therapy three times a week for the first four weeks after discharge from hospital and one session pr week for the next eight weeks in addition to ordinary physical therapy The active comparator group receives only ordinary physical therapy during this period.
Study NCT00184431 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Physical therapy technique and exercises
Description: The experimental group receives task specific physical therapy three times a week for the first four weeks after discharge from hospital and one session pr week for the next eight weeks in addition to ordinary physical therapy The active comparator group receives only ordinary physical therapy during this period.
Study NCT02038101 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Education and Feedback
Description: 1. Formal Rounds on AUC for TTE~2. Appropriate Use for TTE Application for Smartphone~3. Individualized Feedback Reports provided by email
Study NCT01168700 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: aged garlic extract
Description: Aged garlic extract, 1.2 g per day for 12 weeks
Study NCT01168700 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo 1.2 g per day for 12 weeks.
Study NCT01692080 — intervention group
Intervention type: BEHAVIORAL
Intervention: Asthma education
Description: Two separate asthma education classes are conducted to target two age groups: 6-10 yrs and 10-15 yrs. With the guidance of pharmacy faculty, student pharmacists develop innovative educational activities directed at three of the most common barriers to proper asthma control: avoidance of asthma triggers; compliance with asthma medications and proper usage of inhalers; and the importance of an asthma action plan. There is a different group of student pharmacists participating in each camp and this allows for variation in educational activities, all reinforcing the same important aspects of optimal asthma management. Students create age-appropriate activities for each group. Parents are required to attend camps with their child and participate in the asthma education sessions.
Study NCT02446665 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: MR Elastography (MRE) and FibroScan
Study NCT02446665 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MR Elastography (MRE) and FibroScan
Study NCT05617573 — intervention group
Intervention type: PROCEDURE
Intervention: Total knee arthroplasty due to advanced osteoarthritis.
Description: Postoperative usage of intravenous methylprednisolone
Study NCT03912688 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: acupoint stimulation
Study NCT03912688 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: single acupoint
Study NCT03912688 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: dual acupoints
Study NCT00631800 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pagibaximab (formerly BSYX-A110)
Description: Pagibaximab at 60, 90 mg/kg intravenously at Days 0, 7, 14
Study NCT00631800 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Pagibaximab (formerly BSYX-A110)
Description: Pagibaximab at 60, 90 mg/kg intravenously at Days 0, 7, 14
Study NCT02598622 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetylcarnitine
Description: Acetylcarnitine is taken 2 times a day for days 1 through 21.
Study NCT03264872 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Peer-Enhanced Motivational Interviewing
Description: Target clients in this Peer-Enhanced Motivational Interviewing arm will receive separate one-hour Motivational Interviewing (MI) sessions, in which the therapist reviews the target clients substance use behaviors in a non-confrontational manner, listens empathetically, and reinforces any client statements indicating a desire the change. In this arm, the therapist also presents the target client's peer with data about the extent of the target client's substance use, builds the peer's motivation to help their friend, and teaches the peer communication sills they can use to influence the target client's substance use behaviors.
Study NCT03264872 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Waitlist Control
Description: After the 12 week follow up period, if subjects in the Waitlist Control group desire to receive the Peer-Enhanced Motivational Interviewing intervention, that will be made available to them.
Study NCT00935025 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD1305
Description: single and multiple oral doses, extended-release capsule
Study NCT00935025 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: single and multiple oral doses, capsule
Study NCT04529213 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Rapid Maxillary Expansion Treatment
Description: The patients were treated with KBME, Hyrax and MIDME maxillary expansion appliances, respectively. All expansion appliances containing a Hyrax expansion screw positioned parallel to the second premolars and were used to correct the posterior crossbite. In the MIDME group, two mini-screws with a diameter of 1.6 mm and a length of 10 mm are located on the right and left sides between the roots of the 2nd premolar and 1st molar teeth with 60-70° angle. KBME and Hyrax expansion appliances were cemented with glass ionomer cement and MIDME was cemented with using the light-cured composite. Same protocol was applied to all patients during RME treatment. Expansion screws in all groups were activated by two turns a day.
Study NCT06299501 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Routine questions
Description: The routine group of nurses receive training and supervision and will ask questions about family violence to everyone, disregarding if they suspect family violence or not.
Study NCT06299501 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Questions on evidence based indication
Description: The group of nurses will receive training and supervision and will ask questions on evidence based indication
Study NCT06299501 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as usual
Description: The group of nurses will ask questions when suspecting ongoing violence in the family
Study NCT01820676 — intervention group
Intervention type: DEVICE
Intervention: iUni G2+
Description: The iUni G2+ Unicompartmental Resurfacing Device (iUni) is an FDA cleared and CE Marked implant designed for patients with damage isolated to either the medial or lateral tibiofemoral compartment of the knee. The patient-specific iUni is designed from a CT scan of an individual patient's knee using a design process which interactively maps the diseased area and defines the extent of misalignment present in the knee. This process allows definition of the shape and size of the femoral and tibial components of the implant, as well as the disposable instrumentation (Fitz).
Study NCT02709954 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Active inhaled delta-9-THC
Description: Low dose THC (\~4 mg), dissolved in alcohol. This dose is roughly equivalent to smoking approximately 1/4 of a marijuana cigarette, or joint. Administered over 20 minutes via a vaporizer.
Study NCT02709954 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Control: Approximately 4 drinks of orange juice or ginger ale covered by a trace amount of ethanol on the surface, each administered over approximately 10 minutes.
Study NCT03108222 — intervention group
Intervention type: OTHER
Intervention: Phosphorus Absorption Test
Description: Subjects will undergo a radiophosphorus (P-33) absorption test over two days, that will include an oral administration of P-33 on the 1st day of the test, and an IV administration of P-33 on the 2nd day of the test. P-33 activity from serial serum and urine collections will be determined by scintillation counting, and fractional phosphorus absorption calculated by kinetic modeling.
Study NCT01243086 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ranibizumab
Description: Intra-vitreal injections of 0.5mg/0.05 mL dosage, injected at months 0, 1, and 2. For those requiring additional injections, patients will receive monthly treatment up to a maximum of 6 months total.
Study NCT01368601 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: CPAP (Continuous airway pressure)
Description: To evaluate if continuous positive airway pressure (CPAP) on the lung undergoing lobectomy can decrease the inflammatory response and PPC.
Study NCT03922308 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive injection of placebo matched to SHP655.
Study NCT03922308 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive injection of placebo matched to SHP655.
Study NCT03922308 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHP655
Description: Participants will receive injection of SHP655.
Study NCT01243086 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: OZURDEX
Description: OZURDEX injection of 0.7mg dosage at months 0 with follow up for a total of 6 months.
Study NCT02598622 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo is taken 2 times a day for days 1 through 21.
Study NCT01093976 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dronabinol
Description: 2.5mg-15mg by mouth once a day for twelve-weeks
Study NCT05786053 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: graded recession of inferior oblique muscle
Description: . Graded recession of IO muscle depends on the amplitude of the V-pattern and degree of IOOA. Eight mm recession for amplitude 7.5 to 10 degree and mild IOOA (10 degree or +1) ,10 mm recession for amplitude 11- 15 degree and moderate IOOA (11 -15 or +2) and maximum recession for amplitude more than 15 degree and marked IOOA (more than15 degree or +3). Simultaneous correction of the horizontal deviation was performed at the same sitting.
Study NCT03296553 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valganciclovir
Description: The experimental group will receive Valganciclovir 900 mg twice in a day before the initiation of cART until viral load of HHV-8 is undetectable.
Study NCT03296553 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Antiretroviral Combinations
Description: Patients will receive standard antiretroviral treatment as recommended
Study NCT01946282 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: FIT Invitation Only
Description: Patients meeting the inclusion / exclusion criteria are mailed invitations to complete a free colorectal cancer screening. POLYMEDCO Fecal Immunochemical Tests (FIT) are mailed to patient homes with instructions, followed up with live and TELEVOX reminder phone calls.
Study NCT01946282 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: FIT plus $5 Incentive
Description: Patients meeting the inclusion / exclusion criteria are mailed invitations to complete a free colorectal cancer screening. POLYMEDCO Fecal Immunochemical Tests (FIT) are mailed to patient homes with instructions, followed up with live and TELEVOX reminder phone calls. Patients are offered a small incentive to complete their screening.
Study NCT01946282 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: FIT plus $10 Incentive
Description: Patients meeting the inclusion / exclusion criteria are mailed invitations to complete a free colorectal cancer screening. POLYMEDCO Fecal Immunochemical Tests (FIT) are mailed to patient homes with instructions, followed up with live and TELEVOX reminder phone calls. Patients are offered a small incentive to complete their screening.
Study NCT01913873 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: serum concentration changes cardiac biomarkers
Description: Serum concentration determination for cardiac biomarkers (CK-MB and Hs-cTn) preoperatively, at induction of anesthesia (after placement of the arterial line), upon arrival at the intensive care unit (ICU), as well as every 3 hours for 12 hours, then every 6 hours the following 12 hours and a last sample is taken 48 hours after surgery.
Study NCT00701935 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: subcutaneous injection, twice a day
Study NCT03922308 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard of Care
Description: Participants will receive PEX as Standard of Care (SOC).
Study NCT03922308 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Standard of Care
Description: Participants will receive PEX as Standard of Care (SOC).
Study NCT04958213 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dextrose prolotherapy injection
Description: 15% dextrose prolotherapy injection into the knee and 15% dextrose prolotherapy injection will be applied to the painful adhesions of the ligaments around the knee.
Study NCT01812707 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Alirocumab
Description: Two SC injections in the abdomen only
Study NCT01812707 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alirocumab
Description: Two SC injections in the abdomen only
Study NCT04958213 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: OTHER
Intervention: conventional physical therapy
Description: 4 weeks (20 sessions) physical therapy (Hotpack, TENS and Ultrasound) and home exercise program (isometric and isotonic exercises).